HomeESPR • NASDAQ
add
Esperion Therapeutics Inc
Previous close
$2.13
Day range
$1.95 - $2.10
Year range
$0.70 - $3.40
Market cap
376.91M USD
Avg Volume
8.23M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | 32.25M | 71.38% |
Operating expense | 45.42M | 88.18% |
Net income | -56.34M | -1.54% |
Net profit margin | -174.71 | 40.75% |
Earnings per share | -0.50 | 34.21% |
EBITDA | -42.36M | 0.14% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 82.25M | -50.71% |
Total assets | 205.80M | -17.00% |
Total liabilities | 660.79M | 15.58% |
Total equity | -454.99M | — |
Shares outstanding | 185.05M | — |
Price to book | -0.55 | — |
Return on assets | -49.60% | — |
Return on capital | -102.10% | — |
Cash Flow
Net change in cash
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Net income | -56.34M | -1.54% |
Cash from operations | -37.06M | 12.75% |
Cash from investing | 0.00 | 100.00% |
Cash from financing | 4.47M | 114.73% |
Net change in cash | -32.58M | 61.49% |
Free cash flow | -28.45M | 18.84% |
About
Esperion Therapeutics, Inc. is a public American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan. Wikipedia
Founded
May 1998
Headquarters
Website
Employees
240